Previous close | 0.3500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2024-05-17 |
Day's range | 0.1500 - 0.3500 |
Contract range | N/A |
Volume | |
Open interest | 3.84k |
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...